Tokyo, Japan

Hidenori Kimura



 

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 30(Granted Patents)


Location History:

  • Osaka, JP (2009 - 2017)
  • Bunkyo-ku, JP (2020 - 2023)
  • Tokyo, JP (2019 - 2024)

Company Filing History:


Years Active: 2009-2025

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Hidenori Kimura: Innovator in Vaccine Adjuvants

Introduction

Hidenori Kimura is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of vaccine adjuvants. With a total of 11 patents to his name, Kimura's work has had a substantial impact on vaccine efficacy and safety.

Latest Patents

One of Kimura's latest patents involves substituted pyrimidines as vaccine adjuvants. This invention provides a compound of a specific formula that is useful as a vaccine adjuvant. The patent details the structure of the compound, including various substituents and their roles in enhancing vaccine performance. This innovative approach aims to improve the immune response to vaccines, making them more effective in preventing diseases.

Career Highlights

Throughout his career, Hidenori Kimura has worked with notable companies such as Sumitomo Dainippon Pharma Co., Ltd. and Sumitomo Pharma Co., Ltd. His experience in these organizations has allowed him to collaborate with leading experts in the pharmaceutical industry and contribute to groundbreaking research.

Collaborations

Kimura has collaborated with esteemed colleagues, including Yoshiaki Isobe and Hitoshi Watanabe. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of vaccine development.

Conclusion

Hidenori Kimura's contributions to the field of vaccine adjuvants highlight his role as a key innovator in pharmaceutical sciences. His patents and collaborations reflect a commitment to enhancing vaccine efficacy, ultimately benefiting public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…